"uuid:ID","rationale","id","versionIdentifier","instanceType"
"df3a9fff-19c2-4a00-a0ab-a5a269eb6792","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","2","StudyVersion"
